EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency

Basile Chrétien iD, Andry Rabiaza, Nishida Kazuki iD, Sophie Fedrizzi, Marion Sassier, Charles Dolladille, Joachim Alexandre, Xavier Humbert iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0317841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Basile Chrétien und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Medicine and Clinical Research, Section of Biostatistics, Nagoya University Graduate School of Medicine, Aichi, Japan. Hauptthemen laut MEDLINE: Hypertension, Selective Serotonin Reuptake Inhibitors, Pharmacovigilance. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Recent literature has reported instances of drug associated with hypertension with serotonin reuptake inhibitors (SRIs). Nonetheless, the association between SRIs and hypertension development is the subject of ongoing debate. It remains uncertain whether this is indicative of a class effect, and if dose-effect exist. To investigate the potential class effect associating SRIs with hypertension reporting, we utilized real-world data from VigiBase®, the World Health Organization (WHO) pharmacovigilance database.

Methods

We conducted an updated disproportionality analysis within VigiBase® to identify a signal of hypertension reporting with individual SRIs by calculating adjusted reporting odds ratios (aRORs) within a multivariate case/non-case study design. Additionally, we explored the presence of a dose-effect relationship.

Results

The database contained 13,682 reports of SRI associated with hypertension (2.2%), predominantly in women (70.0%). Hypertension was most reported in the 45-64 years old age group (44.8%). A total of 3,879 cases were associated with sertraline, 2,862 with fluoxetine, 2,516 with citalopram, 2,586 with escitalopram, 2,441 with paroxetine, 201 with fluvoxamine and 8 with zimeldine. A significant ROR was observed for all SRIs in both univariate (RORs ranging from 1.39 to 1.54) and multivariable analyses (aRORs ranging from 1.16 to 1.40) after adjustments for age group, sex, concurrent antihypertensive medication and drugs knowns to induce hypertension, except for fluvoxamine and zimeldine. No dose-response relationship was identified.

Conclusion

This investigation, conducted under real life conditions, unveils a notable pharmacovigilance safety signal associating SRI usage with hypertension reporting. No dose-response effect was detectable. Further longitudinal studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionSelective Serotonin Reuptake InhibitorsPharmacovigilanceHumansFemaleMaleMiddle AgedWorld Health OrganizationAdultAgedDatabases, FactualDose-Response Relationship, DrugYoung AdultAdolescent

Substanzen

Selective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Center for Advanced Medicine and Clinical Research, Section of Biostatistics, Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Normandie Univ, UNICAEN, Department of general practice, Caen, France.
  • CHU Caen, Pharmacology Department, Caen, France.
  • Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Caen, France.

ORCID-Profile: Basile Chrétien, Nishida Kazuki, Xavier Humbert

Zitieren

APA

Chrétien, B., Rabiaza, A., Kazuki, N., Fedrizzi, S., Sassier, M., Dolladille, C., Alexandre, J., & Humbert, X. (2025). Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency. PLOS ONE. https://doi.org/10.1371/journal.pone.0317841

Vancouver

Chrétien B, Rabiaza A, Kazuki N, Fedrizzi S, Sassier M, Dolladille C, et al. Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency. PLOS ONE. 2025. doi:10.1371/journal.pone.0317841

BibTeX
@article{Chrtien2025,
  author = {Chrétien, Basile and Rabiaza, Andry and Kazuki, Nishida and Fedrizzi, Sophie and Sassier, Marion and Dolladille, Charles and Alexandre, Joachim and Humbert, Xavier},
  title = {Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0317841}
}
Kostenlos starten →